Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Liabilities (2020 - 2025)

Apellis Pharmaceuticals has reported Total Liabilities over the past 6 years, most recently at $705.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $705.1 million for Q4 2025, up 7.4% from a year ago — trailing twelve months through Dec 2025 was $705.1 million (up 7.4% YoY), and the annual figure for FY2025 was $705.1 million, up 7.4%.
  • Total Liabilities for Q4 2025 was $705.1 million at Apellis Pharmaceuticals, up from $657.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for APLS hit a ceiling of $841.4 million in Q2 2021 and a floor of $565.3 million in Q1 2024.
  • Median Total Liabilities over the past 5 years was $649.8 million (2024), compared with a mean of $644.4 million.
  • Biggest five-year swings in Total Liabilities: surged 76.41% in 2021 and later decreased 20.6% in 2022.
  • Apellis Pharmaceuticals' Total Liabilities stood at $683.1 million in 2021, then decreased by 13.58% to $590.3 million in 2022, then increased by 0.65% to $594.2 million in 2023, then grew by 10.49% to $656.5 million in 2024, then increased by 7.4% to $705.1 million in 2025.
  • The last three reported values for Total Liabilities were $705.1 million (Q4 2025), $657.6 million (Q3 2025), and $665.1 million (Q2 2025) per Business Quant data.